MUMBAI, India , Oct. 23, 2024 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30 th September 2024 . Consolidated Financial Highlights (in ₹ Cr.
or as stated) Particulars Q2FY25 Q2FY24 YoY Growth H1FY25 H1FY24 YoY Growth Revenue from Operations 2,242 1,911 17 % 4,193 3,660 15 % CDMO 1,324 1,068 24 % 2,381 1,967 21 % CHG 643 589 9 % 1,274 1,206 6 % ICH 277 256 8 % 541 495 9 % EBITDA 403 315 28 % 627 485 29 % EBITDA Margin 18 % 16 % - 15 % 13 % - Share of Net Profit of Associates 17 19 (10) % 40 33 18 % PAT 23 5 350 % (66) (94) NM PAT Margin 1 % 0 % - (2) % (3) % - Key Highlights for Q2FY25 Revenue from Operations grew by 17% YoY, primarily driven by robust growth in CDMO business EBITDA grew by 28% YoY with EBITDA margin of 18%, a YoY improvement of about 150bps, driven by operating leverage, cost optimization initiatives and superior revenue mix Released our FY2024 Sustainability Report . The report follows GRI standards and is aligned with SASSB and UNGC frameworks. It also highlights our commitment to reduce our GHG 1 emissions in-line with SBTi's 2 1.
5 o decarbonization pathway Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent gr.